Intuitive Surgical, Inc.
NASDAQ:ISRG · NASDAQ Global Select
+$3.65 today
Vol 3.89M · Avg 2.21M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $2.0B |
| Short-term Investments | $2.5B |
| Receivables | $1.7B |
| Inventory | $1.9B |
| Other Current | $3.3B |
| Total Current Assets | $11.5B |
| PP&E (Net) | $5.4B |
| Goodwill | $613.2M |
| Intangible Assets | $173.5M |
| Long-term Investments | $3.5B |
| Tax Assets | $683.8M |
| Other Non-current | -$3.6B |
| Total Non-current Assets | $6.7B |
| Total Assets | $20.1B |
Analysis
Selected assets total $20.1B for Latest. The largest visible component is PP&E (Net) at $5.4B, about 27.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.4B +66.1% | $2.0B -26.3% | $2.8B +73.9% | $1.6B +22.5% | $1.3B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $2.6B +29.3% | $2.0B -19.7% | $2.5B -2.7% | $2.5B -13.6% | $2.9B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $1.6B +20.0% | $1.4B +7.0% | $1.3B +18.1% | $1.1B +20.2% | $893.0M | $533.8M | $399.4M | -$1.7B |
| Inventory | $1.8B +23.7% | $1.5B +21.8% | $1.2B +36.7% | $893.2M +52.1% | $587.1M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $376.4M +48.4% | $253.7M +43.6% | $176.7M +2796.7% | $6.1M -95.3% | $129.6M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $9.8B +37.5% | $7.1B -9.9% | $7.9B +26.1% | $6.3B +7.0% | $5.8B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $5.3B +11.7% | $4.8B +35.2% | $3.5B +49.0% | $2.4B +26.5% | $1.9B | $1.2B | $1.5B | $687.8M |
| Goodwill | $370.3M +6.6% | $347.5M -0.3% | $348.7M +0.1% | $348.5M +1.4% | $343.6M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $11.1M -51.7% | $23.0M -41.2% | $39.1M -21.5% | $49.8M -29.4% | $70.5M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $3.3B -34.9% | $5.1B +138.9% | $2.1B -19.2% | $2.6B -40.6% | $4.4B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $1.0B -10.7% | $1.1B +25.3% | $910.5M +37.0% | $664.6M +50.6% | $441.4M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $810.8M +119.7% | $369.0M -38.3% | $597.6M -9.5% | $660.3M +17.3% | $562.7M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $10.9B -7.5% | $11.7B +55.3% | $7.6B +12.4% | $6.7B -12.8% | $7.7B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $20.6B +9.5% | $18.8B +22.0% | $15.4B +19.0% | $13.0B -4.3% | $13.6B | $13.3B | $11.9B | $10.6B |
| Account Payables | $255.1M +31.9% | $193.4M +2.5% | $188.7M +28.4% | $147.0M +21.3% | $121.2M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $39.0M +16.4% | $33.5M | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $125.4M | $0 -100.0% | $111.4M +15.9% | $96.1M +77.6% | $54.1M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $506.7M +8.1% | $468.8M +5.1% | $446.1M +12.3% | $397.3M +5.3% | $377.2M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $609.4M +69.5% | $359.6M -17.6% | $436.4M +8.7% | $401.6M +10.9% | $362.1M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $2.0B +14.9% | $1.7B +5.2% | $1.7B +16.6% | $1.4B +23.7% | $1.1B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $131.9M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $172.5M +80.8% | $95.4M | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $91.4M +68.9% | $54.1M +18.6% | $45.6M +11.2% | $41.0M +11.4% | $36.8M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $155.6M -48.4% | $301.7M -11.2% | $339.9M -14.7% | $398.3M +20.7% | $329.9M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $683.3M +21.2% | $563.7M +46.2% | $385.5M -12.2% | $439.3M -3.2% | $453.7M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $2.7B +16.5% | $2.3B +13.0% | $2.0B +9.8% | $1.9B +16.1% | $1.6B | $14.7B | $3.7B | $9.6B |
| Common Stock | $400.0K +0.0% | $400.0K +0.0% | $400.0K +0.0% | $400.0K +0.0% | $400.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $7.0B +3.1% | $6.8B +43.4% | $4.7B +35.5% | $3.5B -26.5% | $4.8B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $43.3M +184.4% | -$51.3M -320.5% | -$12.2M +92.5% | -$162.5M -571.5% | -$24.2M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $117.7M +22.7% | $95.9M +6.9% | $89.7M +26.9% | $70.7M +40.3% | $50.4M | $1.4B | $337.8M | $931.4M |
| Total Equity | $17.9B +8.5% | $16.5B +23.4% | $13.4B +20.6% | $11.1B -7.4% | $12.0B | $9.1B | $7.7B | $3.3B |
| Total Debt | $302.8M +107.4% | $146.0M | $0 | $0 -100.0% | $87.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$3.1B -62.9% | -$1.9B +31.6% | -$2.8B -73.9% | -$1.6B -31.3% | -$1.2B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.04B
ResMed Inc.
NYSE:RMD
$27.27B
West Pharmaceutical Services, Inc.
NYSE:WST
$23.11B
Hologic, Inc.
HOLX
$16.97B
The Cooper Companies, Inc.
NASDAQ:COO
$12.83B
Baxter International Inc.
NYSE:BAX
$10.27B
Repligen Corporation
NASDAQ:RGEN
$7.41B
Teleflex Incorporated
NYSE:TFX
$5.58B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$4.01B
ICU Medical, Inc.
NASDAQ:ICUI
$3.52B
Embecta Corp.
NASDAQ:EMBC
$184.59M
Stereotaxis, Inc.
AMEX:STXS
$181.79M
Bionano Genomics, Inc.
BNGO
$13.43M
NEXGEL, Inc.
NXGL
$5.46M
Innovative Eyewear, Inc.
LUCY
$3.39M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ISRG have?
Intuitive Surgical, Inc. (ISRG) reported $3.37B in cash and equivalents in fiscal 2025.
How much debt does ISRG carry?
Intuitive Surgical, Inc. (ISRG) reported $302.80M of total debt, with net debt of -$3,065,200,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.